DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[9] |
Tretinoin |
DM49DUI
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Tretinoin. |
Acne vulgaris [ED80]
|
[10] |
Sucralfate |
DMP9HBO
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Sucralfate. |
Acne vulgaris [ED80]
|
[11] |
Thioguanine |
DM7NKEV
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Thioguanine. |
Acute myeloid leukaemia [2A60]
|
[12] |
Ivosidenib |
DM8S6T7
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ivosidenib. |
Acute myeloid leukaemia [2A60]
|
[7] |
Uracil mustard |
DMHL7OB
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Uracil mustard. |
Acute myeloid leukaemia [2A60]
|
[10] |
Midostaurin |
DMI6E0R
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Idarubicin |
DMM0XGL
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Daunorubicin |
DMQUSBT
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Daunorubicin. |
Acute myeloid leukaemia [2A60]
|
[7] |
Arn-509 |
DMT81LZ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Arn-509. |
Acute myeloid leukaemia [2A60]
|
[7] |
Gilteritinib |
DMTI0ZO
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[7] |
Oliceridine |
DM6MDCF
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Oliceridine. |
Acute pain [MG31]
|
[7] |
Magnesium Sulfate |
DMVEK07
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Magnesium Sulfate. |
Acute pain [MG31]
|
[11] |
Terfenadine |
DM4KLPT
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Terfenadine. |
Allergic/hypersensitivity disorder [4A80-4A8Z]
|
[7] |
Tacrine |
DM51FY6
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Tacrine. |
Alzheimer disease [8A20]
|
[8] |
Galantamine |
DMEO794
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Galantamine. |
Alzheimer disease [8A20]
|
[8] |
Rivastigmine |
DMG629M
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Rivastigmine. |
Alzheimer disease [8A20]
|
[8] |
Donepezil |
DMIYG7Z
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Donepezil. |
Alzheimer disease [8A20]
|
[8] |
Metronidazole |
DMTIVEN
|
Minor |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Metronidazole. |
Amoebiasis [1A36]
|
[9] |
Ivabradine |
DM0L594
|
Major |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Ivabradine. |
Angina pectoris [BA40]
|
[13] |
Bepridil |
DM0RKS4
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Bepridil. |
Angina pectoris [BA40]
|
[7] |
Dronedarone |
DMA8FS5
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Dronedarone. |
Angina pectoris [BA40]
|
[8] |
Bedaquiline |
DM3906J
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[7] |
Hydroxyzine |
DMF8Y74
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Hydroxyzine. |
Anxiety disorder [6B00-6B0Z]
|
[7] |
Promazine |
DMZAL7W
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Promazine. |
Appearance/behaviour symptom [MB23]
|
[7] |
Cilostazol |
DMZMSCT
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Cilostazol. |
Arterial occlusive disease [BD40]
|
[7] |
Voriconazole |
DMAOL2S
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Voriconazole. |
Aspergillosis [1F20]
|
[7] |
Posaconazole |
DMUL5EW
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Posaconazole. |
Aspergillosis [1F20]
|
[7] |
Terbutaline |
DMD4381
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Terbutaline. |
Asthma [CA23]
|
[14] |
Pirbuterol |
DMI5678
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Pirbuterol. |
Asthma [CA23]
|
[14] |
Isoetharine |
DMITSEH
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Isoetharine. |
Asthma [CA23]
|
[14] |
Salbutamol |
DMN9CWF
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Salbutamol. |
Asthma [CA23]
|
[15] |
Formoterol |
DMSOURV
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Formoterol. |
Asthma [CA23]
|
[14] |
Atomoxetine |
DM5L6HI
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Atomoxetine. |
Attention deficit hyperactivity disorder [6A05]
|
[7] |
Lisdexamfetamine |
DM6W8V5
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Lisdexamfetamine. |
Attention deficit hyperactivity disorder [6A05]
|
[7] |
Desipramine |
DMT2FDC
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Desipramine. |
Attention deficit hyperactivity disorder [6A05]
|
[7] |
Retigabine |
DMGNYIH
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Retigabine. |
Behcet disease [4A62]
|
[7] |
Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[16] |
Loperamide |
DMOJZQ9
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Loperamide. |
Bowel habit change [ME05]
|
[17] |
Temozolomide |
DMKECZD
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Temozolomide. |
Brain cancer [2A00]
|
[10] |
Lomustine |
DMMWSUL
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Lomustine. |
Brain cancer [2A00]
|
[10] |
Eribulin |
DM1DX4Q
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[7] |
Lapatinib |
DM3BH1Y
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Lapatinib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Mitomycin |
DMH0ZJE
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mitomycin. |
Breast cancer [2C60-2C6Y]
|
[10] |
Thiotepa |
DMIZKOP
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Thiotepa. |
Breast cancer [2C60-2C6Y]
|
[10] |
Tamoxifen |
DMLB0EZ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Tamoxifen. |
Breast cancer [2C60-2C6Y]
|
[7] |
Toremifene |
DMQYUWG
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Toremifene. |
Breast cancer [2C60-2C6Y]
|
[8] |
Bosutinib |
DMTI8YE
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[7] |
Sotalol |
DML60TN
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Sotalol. |
Cardiac arrhythmia [BC9Z]
|
[7] |
PF-04449913 |
DMSB068
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and PF-04449913. |
Chronic myelomonocytic leukaemia [2A40]
|
[7] |
Olodaterol |
DM62B78
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Olodaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[14] |
Vilanterol |
DMF5EK1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Vilanterol. |
Chronic obstructive pulmonary disease [CA22]
|
[18] |
Salmeterol |
DMIEU69
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Salmeterol. |
Chronic obstructive pulmonary disease [CA22]
|
[14] |
Indacaterol |
DMQJHR7
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Indacaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[14] |
Arformoterol |
DMYM974
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Arformoterol. |
Chronic obstructive pulmonary disease [CA22]
|
[14] |
Phenylbutazone |
DMAYL0T
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Phenylbutazone. |
Chronic pain [MG30]
|
[19] |
Ketoprofen |
DMRKXPT
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Ketoprofen. |
Chronic pain [MG30]
|
[19] |
Irinotecan |
DMP6SC2
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Irinotecan. |
Colorectal cancer [2B91]
|
[10] |
Oxaliplatin |
DMQNWRD
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Oxaliplatin. |
Colorectal cancer [2B91]
|
[7] |
Capecitabine |
DMTS85L
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Capecitabine. |
Colorectal cancer [2B91]
|
[10] |
Isoproterenol |
DMK7MEY
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Isoproterenol. |
Conduction disorder [BC63]
|
[14] |
Mestranol |
DMG3F94
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Mestranol. |
Contraceptive management [QA21]
|
[20] |
Halothane |
DM80OZ5
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Halothane. |
Corneal disease [9A76-9A78]
|
[7] |
Propofol |
DMB4OLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Propofol. |
Corneal disease [9A76-9A78]
|
[21] |
Sevoflurane |
DMC9O43
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Sevoflurane. |
Corneal disease [9A76-9A78]
|
[7] |
Probucol |
DMVZQ2M
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Probucol. |
Coronary atherosclerosis [BA80]
|
[7] |
Methadone |
DMTW6IU
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Methadone. |
Cough [MD12]
|
[8] |
Clofazimine |
DMEBOFW
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Clofazimine. |
Crohn disease [DD70]
|
[7] |
Mycophenolic acid |
DMRBMAU
|
Moderate |
Altered absorption of Moxifloxacin due to GI flora changes caused by Mycophenolic acid. |
Crohn disease [DD70]
|
[22] |
Mifepristone |
DMGZQEF
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Mifepristone. |
Cushing syndrome [5A70]
|
[8] |
Pasireotide |
DMHM7JS
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Pasireotide. |
Cushing syndrome [5A70]
|
[7] |
Osilodrostat |
DMIJC9X
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Osilodrostat. |
Cushing syndrome [5A70]
|
[7] |
Trimipramine |
DM1SC8M
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Trimipramine. |
Depression [6A70-6A7Z]
|
[7] |
Imipramine |
DM2NUH3
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Imipramine. |
Depression [6A70-6A7Z]
|
[7] |
Fluoxetine |
DM3PD2C
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Fluoxetine. |
Depression [6A70-6A7Z]
|
[7] |
Nortriptyline |
DM4KDYJ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Nortriptyline. |
Depression [6A70-6A7Z]
|
[7] |
Escitalopram |
DMFK9HG
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Escitalopram. |
Depression [6A70-6A7Z]
|
[8] |
Clomipramine |
DMINRKW
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Clomipramine. |
Depression [6A70-6A7Z]
|
[7] |
Trazodone |
DMK1GBJ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Trazodone. |
Depression [6A70-6A7Z]
|
[7] |
Amitriptyline |
DMK7F9S
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Amitriptyline. |
Depression [6A70-6A7Z]
|
[7] |
Amoxapine |
DMKITQE
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Amoxapine. |
Depression [6A70-6A7Z]
|
[7] |
Mirtazapine |
DML53ZJ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Mirtazapine. |
Depression [6A70-6A7Z]
|
[7] |
Protriptyline |
DMNHTZI
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Protriptyline. |
Depression [6A70-6A7Z]
|
[7] |
Doxepin |
DMPI98T
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Doxepin. |
Depression [6A70-6A7Z]
|
[7] |
Venlafaxine |
DMR6QH0
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Venlafaxine. |
Depression [6A70-6A7Z]
|
[7] |
Tetrabenazine |
DMYWQ0O
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[7] |
Deutetrabenazine |
DMUPFLI
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Deutetrabenazine. |
Dystonic disorder [8A02]
|
[7] |
Cannabidiol |
DM0659E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[13] |
Mefenamic acid |
DMK7HFI
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Mefenamic acid. |
Female pelvic pain [GA34]
|
[19] |
Solifenacin |
DMG592Q
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Solifenacin. |
Functional bladder disorder [GC50]
|
[7] |
Pentamidine |
DMHZJCG
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Pentamidine. |
Fungal infection [1F29-1F2F]
|
[7] |
Ketoconazole |
DMPZI3Q
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ketoconazole. |
Fungal infection [1F29-1F2F]
|
[7] |
Sunitinib |
DMCBJSR
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[7] |
Procarbazine |
DMIK367
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Procarbazine. |
Hodgkin lymphoma [2B30]
|
[10] |
Bleomycin |
DMNER5S
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Bleomycin. |
Hodgkin lymphoma [2B30]
|
[10] |
Fostemsavir |
DM50ILT
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Fostemsavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[7] |
Efavirenz |
DMC0GSJ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Efavirenz. |
Human immunodeficiency virus disease [1C60-1C62]
|
[7] |
Saquinavir |
DMG814N
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Saquinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Didanosine |
DMI2QPE
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Didanosine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[24] |
Lopinavir |
DMITQS0
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Lopinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[7] |
Rilpivirine |
DMJ0QOW
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[7] |
Bempedoic acid |
DM1CI9R
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Bempedoic acid. |
Hyper-lipoproteinaemia [5C80]
|
[25] |
Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[26] |
Teriflunomide |
DMQ2FKJ
|
Major |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[8] |
BMS-201038 |
DMQTAGO
|
Major |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[27] |
Quinapril |
DMR8H31
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Quinapril. |
Hypertension [BA00-BA04]
|
[13] |
Fludrocortisone |
DMUDIR8
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Fludrocortisone. |
Hypo-osmolality/hyponatraemia [5C72]
|
[28] |
Meclofenamic acid |
DM05FXR
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Meclofenamic acid. |
Inflammatory spondyloarthritis [FA92]
|
[29] |
Melatonin |
DMKWFBT
|
Minor |
Decreased metabolism of Moxifloxacin caused by Melatonin mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[9] |
Iron |
DMAP8MV
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Iron. |
Iron deficiency anaemia [3A00]
|
[30] |
Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[8] |
Phenolphthalein |
DM5SICT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Phenolphthalein. |
Irritable bowel syndrome [DD91]
|
[8] |
DTI-015 |
DMXZRW0
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by DTI-015. |
Liver cancer [2C12]
|
[10] |
Crizotinib |
DM4F29C
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Crizotinib. |
Lung cancer [2C25]
|
[31] |
Porfimer Sodium |
DM7ZWNY
|
Moderate |
Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Porfimer Sodium. |
Lung cancer [2C25]
|
[32] |
Ceritinib |
DMB920Z
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ceritinib. |
Lung cancer [2C25]
|
[8] |
Lurbinectedin |
DMEFRTZ
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Lurbinectedin. |
Lung cancer [2C25]
|
[10] |
Osimertinib |
DMRJLAT
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Osimertinib. |
Lung cancer [2C25]
|
[7] |
Selpercatinib |
DMZR15V
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Selpercatinib. |
Lung cancer [2C25]
|
[7] |
Lumefantrine |
DM29GAD
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Lumefantrine. |
Malaria [1F40-1F45]
|
[9] |
Halofantrine |
DMOMK1V
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Halofantrine. |
Malaria [1F40-1F45]
|
[33] |
Hydroxychloroquine |
DMSIVND
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Hydroxychloroquine. |
Malaria [1F40-1F45]
|
[7] |
Quinine |
DMSWYF5
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Quinine. |
Malaria [1F40-1F45]
|
[7] |
Primaquine |
DMWQ16I
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Primaquine. |
Malaria [1F40-1F45]
|
[7] |
Mefloquine |
DMWT905
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Mefloquine. |
Malaria [1F40-1F45]
|
[7] |
Inotuzumab ozogamicin |
DMAC130
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[7] |
Calaspargase pegol |
DMQZBXI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[34] |
Fludarabine |
DMVRLT7
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Fludarabine. |
Malignant haematopoietic neoplasm [2B33]
|
[10] |
Pentostatin |
DM0HXDS
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Pentostatin. |
Mature B-cell leukaemia [2A82]
|
[10] |
Idelalisib |
DM602WT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[35] |
Chlorambucil |
DMRKE63
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Chlorambucil. |
Mature B-cell leukaemia [2A82]
|
[10] |
Arsenic trioxide |
DM61TA4
|
Major |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Arsenic trioxide. |
Mature B-cell lymphoma [2A85]
|
[36] |
Clofarabine |
DMCVJ86
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[37] |
Vincristine |
DMINOX3
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vincristine. |
Mature B-cell lymphoma [2A85]
|
[10] |
Teniposide |
DMLW57T
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Teniposide. |
Mature B-cell lymphoma [2A85]
|
[10] |
Mercaptopurine |
DMTM2IK
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mercaptopurine. |
Mature B-cell lymphoma [2A85]
|
[10] |
Cytarabine |
DMZD5QR
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cytarabine. |
Mature B-cell lymphoma [2A85]
|
[10] |
Mechlorethamine |
DM0CVXA
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mechlorethamine. |
Mature T-cell lymphoma [2A90]
|
[10] |
Vemurafenib |
DM62UG5
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Vemurafenib. |
Melanoma [2C30]
|
[8] |
Dacarbazine |
DMNPZL4
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Dacarbazine. |
Melanoma [2C30]
|
[10] |
LGX818 |
DMNQXV8
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and LGX818. |
Melanoma [2C30]
|
[7] |
Ethinyl estradiol |
DMODJ40
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Ethinyl estradiol. |
Menopausal disorder [GA30]
|
[20] |
Lanthanum carbonate |
DMMJQSH
|
Moderate |
Decreased absorption of Moxifloxacin due to formation of complexes caused by Lanthanum carbonate. |
Mineral absorption/transport disorder [5C64]
|
[8] |
Thalidomide |
DM70BU5
|
Moderate |
Increased risk of peripheral neuropathy by the combination of Moxifloxacin and Thalidomide. |
Multiple myeloma [2A83]
|
[9] |
Melphalan |
DMOLNHF
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Melphalan. |
Multiple myeloma [2A83]
|
[10] |
Siponimod |
DM2R86O
|
Major |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Siponimod. |
Multiple sclerosis [8A40]
|
[9] |
Fingolimod |
DM5JVAN
|
Major |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Fingolimod. |
Multiple sclerosis [8A40]
|
[8] |
Ozanimod |
DMT6AM2
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ozanimod. |
Multiple sclerosis [8A40]
|
[7] |
Deflazacort |
DMV0RNS
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Deflazacort. |
Muscular dystrophy [8C70]
|
[28] |
Methoxsalen |
DME8FZ9
|
Moderate |
Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Methoxsalen. |
Mycosis fungoides [2B01]
|
[9] |
Romidepsin |
DMT5GNL
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Romidepsin. |
Mycosis fungoides [2B01]
|
[7] |
Dasatinib |
DMJV2EK
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Hydroxyurea |
DMOQVU9
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Hydroxyurea. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Busulfan |
DMXYJ9C
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Busulfan. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Droperidol |
DM0DXA8
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Droperidol. |
Nausea/vomiting [MD90]
|
[8] |
Prochlorperazine |
DM53SRA
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Prochlorperazine. |
Nausea/vomiting [MD90]
|
[7] |
Promethazine |
DM6I5GR
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Promethazine. |
Nausea/vomiting [MD90]
|
[7] |
Palonosetron |
DMBHMOX
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Palonosetron. |
Nausea/vomiting [MD90]
|
[7] |
Granisetron |
DMIUW25
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Granisetron. |
Nausea/vomiting [MD90]
|
[7] |
Dolasetron |
DMMG26Z
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Dolasetron. |
Nausea/vomiting [MD90]
|
[7] |
Ondansetron |
DMOTQ1I
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ondansetron. |
Nausea/vomiting [MD90]
|
[7] |
Bupropion |
DM5PCS7
|
Major |
Increased risk of lowers seizure threshold by the combination of Moxifloxacin and Bupropion. |
Nicotine use disorder [6C4A]
|
[38] |
Entrectinib |
DMMPTLH
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[7] |
Levomethadyl Acetate |
DM06HG5
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Levomethadyl Acetate. |
Opioid use disorder [6C43]
|
[13] |
Lofexidine |
DM1WXA6
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Lofexidine. |
Opioid use disorder [6C43]
|
[7] |
Rofecoxib |
DM3P5DA
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Rofecoxib. |
Osteoarthritis [FA00-FA05]
|
[19] |
Valdecoxib |
DMAY7H4
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Valdecoxib. |
Osteoarthritis [FA00-FA05]
|
[19] |
Diclofenac |
DMPIHLS
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Diclofenac. |
Osteoarthritis [FA00-FA05]
|
[19] |
Naproxen |
DMZ5RGV
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Naproxen. |
Osteoarthritis [FA00-FA05]
|
[19] |
Rucaparib |
DM9PVX8
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Rucaparib. |
Ovarian cancer [2C73]
|
[7] |
Altretamine |
DMKLAYG
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Altretamine. |
Ovarian cancer [2C73]
|
[10] |
Topotecan |
DMP6G8T
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Topotecan. |
Ovarian cancer [2C73]
|
[10] |
Dextropropoxyphene |
DM23HCX
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Dextropropoxyphene. |
Pain [MG30-MG3Z]
|
[7] |
Aspirin |
DM672AH
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Aspirin. |
Pain [MG30-MG3Z]
|
[29] |
Etodolac |
DM6WJO9
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Etodolac. |
Pain [MG30-MG3Z]
|
[19] |
Diflunisal |
DM7EN8I
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Diflunisal. |
Pain [MG30-MG3Z]
|
[19] |
Ibuprofen |
DM8VCBE
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Ibuprofen. |
Pain [MG30-MG3Z]
|
[19] |
Nabumetone |
DMAT2XH
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Nabumetone. |
Pain [MG30-MG3Z]
|
[19] |
Buprenorphine |
DMPRI8G
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Buprenorphine. |
Pain [MG30-MG3Z]
|
[7] |
Piroxicam |
DMTK234
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Piroxicam. |
Pain [MG30-MG3Z]
|
[19] |
Streptozocin |
DMOF7AT
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Streptozocin. |
Pancreatic cancer [2C10]
|
[10] |
Triclabendazole |
DMPWGBR
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[7] |
Pimavanserin |
DMR7IVC
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Pimavanserin. |
Parkinsonism [8A00]
|
[7] |
Lindane |
DMB8CNL
|
Moderate |
Increased risk of lowers seizure threshold by the combination of Moxifloxacin and Lindane. |
Pediculosis [1G00]
|
[39] |
Famotidine |
DMRL3AB
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Famotidine. |
Peptic ulcer [DA61]
|
[9] |
Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[40] |
Prednisone |
DM2HG4X
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Prednisone. |
Postoperative inflammation [1A00-CA43]
|
[28] |
Choline salicylate |
DM8P137
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Choline salicylate. |
Postoperative inflammation [1A00-CA43]
|
[19] |
Betamethasone |
DMAHJEF
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Betamethasone. |
Postoperative inflammation [1A00-CA43]
|
[28] |
Hydrocortisone |
DMGEMB7
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Hydrocortisone. |
Postoperative inflammation [1A00-CA43]
|
[28] |
Ketorolac |
DMI4EL5
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Ketorolac. |
Postoperative inflammation [1A00-CA43]
|
[19] |
Bromfenac |
DMKB79O
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Bromfenac. |
Postoperative inflammation [1A00-CA43]
|
[19] |
Ritodrine |
DM4V6RL
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ritodrine. |
Preterm labour/delivery [JB00]
|
[14] |
Degarelix |
DM3O8QY
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Degarelix. |
Prostate cancer [2C82]
|
[7] |
Nilutamide |
DMFN07X
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Nilutamide. |
Prostate cancer [2C82]
|
[7] |
Relugolix |
DMK7IWL
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Relugolix. |
Prostate cancer [2C82]
|
[7] |
Bicalutamide |
DMZMSPF
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Bicalutamide. |
Prostate cancer [2C82]
|
[7] |
Alfuzosin |
DMZVMKF
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Alfuzosin. |
Prostate hyperplasia [GA90]
|
[7] |
Verteporfin |
DMIY6DB
|
Moderate |
Increased risk of photosensitivity reactions by the combination of Moxifloxacin and Verteporfin. |
Psoriasis [EA90]
|
[13] |
Levomepromazine |
DMIKFEL
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[7] |
Fluphenazine |
DMIT8LX
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Fluphenazine. |
Psychotic disorder [6A20-6A25]
|
[7] |
Triflupromazine |
DMKFQJP
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Triflupromazine. |
Psychotic disorder [6A20-6A25]
|
[7] |
Sorafenib |
DMS8IFC
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Sorafenib. |
Renal cell carcinoma [2C90]
|
[7] |
Salsalate |
DM13P4C
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Salsalate. |
Rheumatoid arthritis [FA20]
|
[19] |
Meloxicam |
DM2AR7L
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Meloxicam. |
Rheumatoid arthritis [FA20]
|
[19] |
Sulindac |
DM2QHZU
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Sulindac. |
Rheumatoid arthritis [FA20]
|
[19] |
Celecoxib |
DM6LOQU
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Celecoxib. |
Rheumatoid arthritis [FA20]
|
[19] |
Oxaprozin |
DM9UB0P
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Oxaprozin. |
Rheumatoid arthritis [FA20]
|
[19] |
Flurbiprofen |
DMGN4BY
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Flurbiprofen. |
Rheumatoid arthritis [FA20]
|
[19] |
Fenoprofen |
DML5VQ0
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Fenoprofen. |
Rheumatoid arthritis [FA20]
|
[19] |
Dexamethasone |
DMMWZET
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Dexamethasone. |
Rheumatoid arthritis [FA20]
|
[28] |
Leflunomide |
DMR8ONJ
|
Major |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Leflunomide. |
Rheumatoid arthritis [FA20]
|
[8] |
Indomethacin |
DMSC4A7
|
Moderate |
Additive CNS depression effects by the combination of Moxifloxacin and Indomethacin. |
Rheumatoid arthritis [FA20]
|
[19] |
Tolmetin |
DMWUIJE
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Tolmetin. |
Rheumatoid arthritis [FA20]
|
[19] |
Mesoridazine |
DM2ZGAN
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Mesoridazine. |
Schizophrenia [6A20]
|
[8] |
Thioridazine |
DM35M8J
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Thioridazine. |
Schizophrenia [6A20]
|
[8] |
Aripiprazole |
DM3NUMH
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Aripiprazole. |
Schizophrenia [6A20]
|
[9] |
Iloperidone |
DM6AUFY
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Iloperidone. |
Schizophrenia [6A20]
|
[8] |
Paliperidone |
DM7NPJS
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Paliperidone. |
Schizophrenia [6A20]
|
[7] |
Haloperidol |
DM96SE0
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Haloperidol. |
Schizophrenia [6A20]
|
[8] |
Perphenazine |
DMA4MRX
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Perphenazine. |
Schizophrenia [6A20]
|
[7] |
Chlorpromazine |
DMBGZI3
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Chlorpromazine. |
Schizophrenia [6A20]
|
[7] |
Clozapine |
DMFC71L
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Clozapine. |
Schizophrenia [6A20]
|
[7] |
Trifluoperazine |
DMKBYWI
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Trifluoperazine. |
Schizophrenia [6A20]
|
[7] |
Ziprasidone |
DMM58JY
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ziprasidone. |
Schizophrenia [6A20]
|
[8] |
Risperidone |
DMN6DXL
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Risperidone. |
Schizophrenia [6A20]
|
[7] |
Olanzapine |
DMPFN6Y
|
Moderate |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Olanzapine. |
Schizophrenia [6A20]
|
[9] |
Amisulpride |
DMSJVAM
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Amisulpride. |
Schizophrenia [6A20]
|
[7] |
Asenapine |
DMSQZE2
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Asenapine. |
Schizophrenia [6A20]
|
[7] |
Pimozide |
DMW83TP
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Pimozide. |
Schizophrenia [6A20]
|
[13] |
Salicyclic acid |
DM2F8XZ
|
Moderate |
Additive CNS stimulant effects by the combination of Moxifloxacin and Salicyclic acid. |
Seborrhoeic dermatitis [EA81]
|
[29] |
Vardenafil |
DMTBGW8
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Vardenafil. |
Sexual dysfunction [HA00-HA01]
|
[7] |
Floxuridine |
DM04LR2
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Floxuridine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Dactinomycin |
DM2YGNW
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Dactinomycin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Methylprednisolone |
DM4BDON
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Methylprednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[28] |
Cyclophosphamide |
DM4O2Z7
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cyclophosphamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Vinblastine |
DM5TVS3
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vinblastine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Ifosfamide |
DMCT3I8
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Ifosfamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Docetaxel |
DMDI269
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Docetaxel. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Trabectedin |
DMG3Y89
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[13] |
Mitoxantrone |
DMM39BF
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Mitoxantrone. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
LEE011 |
DMMX75K
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and LEE011. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Etoposide |
DMNH3PG
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Etoposide. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Epirubicin |
DMPDW6T
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Epirubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Prednisolone |
DMQ8FR2
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Moxifloxacin and Prednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[28] |
Cisplatin |
DMRHGI9
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Cisplatin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Vandetanib |
DMRICNP
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Vandetanib. |
Solid tumour/cancer [2A00-2F9Z]
|
[41] |
Gemcitabine |
DMSE3I7
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Gemcitabine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Triptorelin |
DMTK4LS
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Triptorelin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Fluorouracil |
DMUM7HZ
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Fluorouracil. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Taxol |
DMUOT9V
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Taxol. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Doxorubicin |
DMVP5YE
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Vinorelbine |
DMVXFYE
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Vinorelbine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Pitolisant |
DM8RFNJ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Pitolisant. |
Somnolence [MG42]
|
[7] |
Telavancin |
DM58VQX
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[7] |
Naltrexone |
DMUL45H
|
Moderate |
Increased risk of hepatotoxicity by the combination of Moxifloxacin and Naltrexone. |
Substance abuse [6C40]
|
[42] |
Ibutilide |
DMKXY2R
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Ibutilide. |
Supraventricular tachyarrhythmia [BC81]
|
[8] |
Adenosine |
DMM2NSK
|
Major |
Increased risk of ventricular arrhythmias by the combination of Moxifloxacin and Adenosine. |
Supraventricular tachyarrhythmia [BC81]
|
[43] |
Plicamycin |
DM7C8YV
|
Minor |
Decreased absorption of Moxifloxacin due to intestinal mucosa variation caused by Plicamycin. |
Testicular cancer [2C80]
|
[10] |
Anagrelide |
DMSQ8MD
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Anagrelide. |
Thrombocytosis [3B63]
|
[7] |
Lenvatinib |
DMB1IU4
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Lenvatinib. |
Thyroid cancer [2D10]
|
[7] |
Cabozantinib |
DMIYDT4
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Cabozantinib. |
Thyroid cancer [2D10]
|
[7] |
Papaverine |
DMCA9QP
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Papaverine. |
Tonus and reflex abnormality [MB47]
|
[44] |
Tizanidine |
DMR2IQ4
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Tizanidine. |
Tonus and reflex abnormality [MB47]
|
[7] |
Mycophenolate mofetil |
DMPQAGE
|
Moderate |
Altered absorption of Moxifloxacin due to GI flora changes caused by Mycophenolate mofetil. |
Transplant rejection [NE84]
|
[22] |
Tacrolimus |
DMZ7XNQ
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Tacrolimus. |
Transplant rejection [NE84]
|
[7] |
Astemizole |
DM2HN6Q
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Astemizole. |
Vasomotor/allergic rhinitis [CA08]
|
[7] |
Trimeprazine |
DMEMV9D
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Trimeprazine. |
Vasomotor/allergic rhinitis [CA08]
|
[7] |
Disopyramide |
DM5SYZP
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Disopyramide. |
Ventricular tachyarrhythmia [BC71]
|
[7] |
Procainamide |
DMNMXR8
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Procainamide. |
Ventricular tachyarrhythmia [BC71]
|
[7] |
Propafenone |
DMPIBJK
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Propafenone. |
Ventricular tachyarrhythmia [BC71]
|
[7] |
Flecainide |
DMSQDLE
|
Major |
Increased risk of prolong QT interval by the combination of Moxifloxacin and Flecainide. |
Ventricular tachyarrhythmia [BC71]
|
[7] |
----------- |
|
|
|
|
|